Researchers from Sutro Biopharma Inc. presented data on dual-payload antibody-drug conjugates (ADCs) engineered to overcome drug resistance, demonstrating enhanced cytotoxicity and potential efficacy in resistant cancer models.
Mitogen-activated protein kinase kinase kinase kinase 1 (HPK1) is a serine/threonine protein kinase that is expressed in the hematopoietic compartment, exerting regulatory functions in myeloid and innate immune cells. It has been associated with decreased T-cell activation and proliferation.
Autoantibodies and B cells are drivers of progressive autoimmune diseases, but targeting B cells or plasma cells alone is not sufficient to address them. Earendil Labs has presented data on HXN-1031, a novel T-cell engager targeting both CD19 and B-cell maturation protein (BCMA).
CAR T cells have been groundbreaking for the treatment of B-cell cancers. But 8 years after Kymriah (tisagenlecleucel, Novartis AG) became the first CAR T-cell therapy to be approved, there are no CAR Ts approved for solid tumors.
CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co. Ltd. has divulged new proteolysis targeting chimeras (PROTACs) comprising an E3 ubiquitin ligase-binding moiety coupled to an EGFR-targeting moiety via a linker.
Researchers from Promatix Biosciences Ltd. presented preclinical data on PBS29301A, a first-in-class bispecific ADC developed using Promatix’s proprietary proteomics-based discovery platform.
In a recent study published in Molecular Therapy: Oncology, researchers from the City of Hope National Medical Center and Beckman Research Institute (USA) and collaborators aimed to identify differentially expressed genetic pathways in glioblastoma multiforme (GBM) tumor cells after 48 hours of hypoxia treatment by performing RNA sequencing.
RSS
